Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wall St rises on vaccine cheer, upbeat business activity data

11/23/2020 | 10:36am EST

(Updates to open)

* Vaccine could reach first Americans by mid-December

* Surging coronavirus cases cap stock market gains

* U.S. business activity expands rapidly in November - data

* Indexes up: Dow 0.86%, S&P 0.53%, Nasdaq 0.09%

Nov 23 (Reuters) - Wall Street's main indexes rose on Monday as hopes of a COVID-19 vaccine and data showing a rapid expansion in monthly business activity fueled bets of a quicker economic recovery from a pandemic-driven recession.

Economically-sensitive sectors including industrials and energy jumped more than 1.5% as investors rotated out of the technology mega-caps that were perceived as safe bets following a coronavirus-led crash earlier this year.

"November has been that month when we were finally convinced that there is light at the end of the tunnel (and) today is another one of those days," said Art Hogan, chief market strategist at National Securities in New York.

"The market has moved higher with confidence that as we get better at treating and preventing this virus, economic activity will likely follow in the wake of that."

Data on Monday showed U.S. business activity in November expanded at the fastest rate in more than five years, topping even the most optimistic forecasts in a Reuters poll.

At 10:22 a.m. ET, the Dow Jones Industrial Average was up 250.54 points, or 0.86%, at 29,514.02, the S&P 500 was up 18.96 points, or 0.53%, at 3,576.50, and the Nasdaq Composite was up 11.06 points, or 0.09%, at 11,866.03.

Global equity markets had earlier received a boost as AstraZeneca Plc became the latest major drugmaker to say its COVID-19 vaccine could be around 90% effective, although its shares fell 3.8% as some traders perceived the efficacy data as disappointing compared with rivals.

"There's good news on the coronavirus vaccine and that's building a lot of enthusiasm in a short trading week, but the enthusiasm might be getting a little bit overdone," said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.

"It isn't like the vaccine is going to be distributed tomorrow. It's going to take at least a month and so we are still pretty far away before reality sets in."

Market participants also warned of higher volatility in a trading week shortened by the Thanksgiving holiday on Nov. 26.

Evidence of high efficacy rates in experimental vaccines had lifted the S&P 500 to a record high earlier this month, although gains have since been capped by new coronavirus-led restrictions to contain a surge in infections.

Meanwhile, hopes of more monetary stimulus were dampened after Treasury Secretary Steven Mnuchin last week pulled the plug on some of the Federal Reserve's pandemic emergency lending programs.

In company news, shares of drugmaker Regeneron Pharmaceuticals Inc rose 0.5% after the FDA on Saturday granted emergency use authorization to its COVID-19 antibody therapy.

Advancing issues outnumbered decliners 3.67-to-1 on the NYSE and 1.75-to-1 on the Nasdaq.

The S&P index recorded 26 new 52-week highs and no new low, while the Nasdaq recorded 125 new highs and seven new lows. (Reporting by Sagarika Jaisinghani and Shivani Kumaresan in Bengaluru; Additional reporting by Devik Jain in Bengaluru; Editing by Arun Koyyur)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
DJ INDUSTRIAL -0.57% 30996.98 Delayed Quote.1.86%
NASDAQ 100 -0.29% 13366.396971 Delayed Quote.3.71%
NASDAQ COMP. 0.09% 13543.061633 Delayed Quote.4.99%
REGENERON PHARMACEUTICALS 0.43% 537.78 Delayed Quote.11.32%
S&P 500 -0.30% 3841.47 Delayed Quote.2.27%
All news about REGENERON PHARMACEUTICALS
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
DJ
01/19REGENERON PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2020 Financia..
PR
01/19REGENERON PHARMACEUTICALS : Morgan Stanley Adjusts Regeneron Pharmaceuticals PT ..
MT
01/15REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (fo..
AQ
01/13S&P closes higher with defensive sectors leading gains
RE
01/13Wall St gains steadily while impeachment hearings get underway
RE
01/13SECTOR UPDATE : Health Care Stocks Trading Lower Premarket Wednesday
MT
01/13REGENERON PHARMACEUTICALS : Benchmark Upgrades Regeneron Pharmaceuticals to Buy ..
MT
More news
Financials (USD)
Sales 2020 8 519 M - -
Net income 2020 3 191 M - -
Net cash 2020 5 478 M - -
P/E ratio 2020 19,1x
Yield 2020 -
Capitalization 56 760 M 56 760 M -
EV / Sales 2020 6,02x
EV / Sales 2021 4,43x
Nbr of Employees 8 314
Free-Float 83,1%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 654,96 $
Last Close Price 537,78 $
Spread / Highest target 47,5%
Spread / Average Target 21,8%
Spread / Lowest Target -7,03%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS11.32%56 760
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
BEIGENE, LTD.44.94%34 148
GENMAB A/S7.31%28 292